December 2024 FDA Recall Drug by Pd-rx Pharmaceuticals, Inc.
D-0163-2025 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Pd-rx Pharmaceuticals, Inc. on December 4, 2024 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Distributed within US: FL, MS, WI and the recall is currently terminated.

Recall Number: D-0163-2025

Reason for Recall
CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit
Initiated
12-04-2024
Reported
01-01-2025
Quantity
70, 90-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
PD-Rx Pharmaceuticals, Inc.
Distributed within US: FL, MS, WI
DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90

Batch or Lot Expiration Information

Lot# I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025